Cardiovascular Diseases (CVD)NCT07294937
Study Protocol: 10-Year Follow-Up of Patients Screened for Cardiovascular Risk by the "All With Heart" Association - Development of a Morocco-Specific Risk Score
An observational study of Cardiovascular Diseases (CVD), run by Moroccan Society of Cardiology at 2 sites in Morocco.
Trial summary
Cardiovascular diseases (CVDs) are the leading cause of death worldwide, and their prevalence is steadily increasing in Morocco. Between 2010 and 2012, the "All with heart" Association conducted a large-scale cardiovascular screening campaign in the Greater Casablanca region, involving more than 10,000 adults aged… Read more about this study
- Who is it for?
- Ages 40 years and older
- Conditions the study is for
- Cardiovascular Diseases (CVD)
- How many people
- 10,000 participants
- Where
- 2 sitesMorocco
- Study dates
- 1 Oct 2025to Oct 2026
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population includes adults aged 40 years and older who were screened for cardiovascular risk between 2010 and 2012 by the "All with heart" Association in the Greater Casablanca region, Morocco. Approximately 10,000 individuals participated in the original screening campaign, which collected data on anthropometric, biological, and lifestyle risk factors. For the 10-year follow-up, all eligible Moroccan participants from the initial screening will be contacted by phone, WhatsApp, or SMS to collect updated information on cardiovascular events, hospitalizations, and mortality. This population represents a community-based cohort reflecting the general adult population at risk of cardiovascular disease in Morocco.
Who may be able to join
- Adults aged 40 years or older at the time of the initial screening (2010-2012).
- Individuals who participated in the cardiovascular risk screening campaign conducted by the "All with heart" Association between 2010 and 2012 in the Greater Casablanca region.
- Moroccan nationality.
- Participants or family members who provide written informed consent for participation in the 10-year follow-up study.
Who cannot join
- Individuals who refuse to participate in the follow-up study.
- Participants who have moved and cannot be reached by phone, WhatsApp, or SMS.
- Participants who died from non-cardiovascular causes.
- Non-Moroccan participants.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Mohamed ALAMI contact
Morocco2 sites, 2 recruiting
- Recruiting
Moroccan Society of Cardiology
Casablanca, 20200
Mohamed ALAMI, Professor of Cardiology, +212661157806, cabinetalami@gmail.com
- Recruiting
Cardiology Centre, Mohammed V Military Hospital, Rabat, Morocco
Rabat
Najat MOUINE, Professor of Cardiology, +212661202733, mouine2@yahoo.fr
About this study
Cardiovascular diseases (CVDs) are the leading cause of death worldwide, and their prevalence is steadily increasing in Morocco. Between 2010 and 2012, the "All with heart" Association conducted a large-scale cardiovascular screening campaign in the Greater Casablanca region, involving more than 10,000 adults aged over 40 years. This 10-year follow-up study aims to evaluate long-term cardiovascular outcomes and to develop a Morocco-specific cardiovascular risk score. Follow-up data will be collected through phone calls, WhatsApp, or SMS with participants or their families to document cardiovascular deaths, myocardial infarctions, and strokes. Statistical analyses, including survival analysis and multivariate logistic regression, will be used to identify significant risk factors and to construct a predictive risk model tailored to the Moroccan population. The study received a favorable opinion from the Rabat Ethics Committee. Written informed consent will be obtained from all participants or their families prior to data collection. The findings are expected to enhance understanding of cardiovascular risk evolution in Morocco and to provide a validated, population-specific risk score to support prevention and patient management strategies.
- Conditions
- Cardiovascular Diseases (CVD)
- Medical subject headings
- Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Participants screened for cardiovascular risk (TAC cohort) | Participants aged 40 years and older who were screened for cardiovascular risk between 2010 and 2012 by the "All with heart" Association in the Greater Casablanca region. This cohort is being followed 10 years after the initial screening to assess cardiovascular outcomes (death, myocardial infarction, stroke) and to develop a Morocco-specific cardiovascular risk score. No intervention is applied; the study is purely observational. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Major Cardiovascular Events (MACE)
Occurrence of major cardiovascular events (myocardial infarction, stroke, or cardiovascular death) among participants screened for cardiovascular risk between 2010 and 2012 by the "All with heart" Association. Events will be identified during the 10-year follow-up period through participant or family contact (phone, WhatsApp, or SMS) and verified through available medical records when possible.
Measured: 10 years after initial screening (2010-2012)
Development and Validation of a Morocco-Specific Cardiovascular Risk Score
Development and internal validation of the Morocco-Specific Cardiovascular Risk Score, a composite risk prediction score estimating the 10-year probability of major cardiovascular events including myocardial infarction, stroke, or cardiovascular death. The score will be derived from baseline cardiovascular risk factors collected during the initial screening and weighted using multivariable regression models based on outcomes observed during the 10-year follow-up. The score will be expressed on a scale ranging from 0 to 100, where higher scores indicate a higher cardiovascular risk and therefore a worse outcome. Model performance will be assessed using discrimination and calibration measures, including the area under the receiver operating characteristic curve and calibration analyses.
Measured: Baseline (2010-2012) and 10-year follow-up (2022)
Secondary outcomes (1)
Incidence of Minor Cardiovascular Events
Occurrence of minor cardiovascular events, including stable or unstable angina, among participants screened between 2010 and 2012. Events will be collected through participant or family interviews and verified with medical records when available.
Measured: 10 years after initial screening (2010-2012)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Dec 2025
- Study start1 Oct 2025
- Primary completionMar 2026 (estimated)
- Study completionOct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiovascular Diseases (CVD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 10,000 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Moroccan Society of Cardiology
- Sponsor type
- University, hospital or other
- Collaborators
- F&C Clinical Trials
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07294937
- Sponsor's protocol ID
- 126/24
- Status last verified
- Dec 2025
- First submitted
- 2 Dec 2025
- Last updated
- 19 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The sharing of individual participant data (IPD) is not authorized by the Ethics Committee of Rabat. According to the committee's decision, data collected in this study are strictly confidential and may only be used by the research team for the purposes defined in the approved protocol. All collected data will remain stored securely and will not be shared with other researchers or institutions to ensure compliance with national data protection regulations and the ethical approval obtained for this study.
Study at a glance
From the registry record, last updated by the sponsor on 19 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study Protocol: 10-Year Follow-Up of Patients Screened for Cardiovascular Risk by the "All With Heart" Association - Development of a Morocco-Specific Risk Score
- ClinicalTrials.gov ID
- NCT07294937
- Acronym / sponsor ID
- 126/24
- Conditions
- Cardiovascular Diseases (CVD)
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 10,000 participants (estimated)
- Lead sponsor
- Moroccan Society of CardiologyUniversity, hospital or other
- Collaborators
- F&C Clinical Trials
- Study start
- 1 Oct 2025 (actual)
- Primary completion
- Mar 2026 (estimated)
- Study completion
- Oct 2026 (estimated)
- First posted
- 19 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cardiovascular diseases (CVDs) are the leading cause of death worldwide, and their prevalence is steadily increasing in Morocco. Between 2010 and 2012, the "All with heart" Association conducted a large-scale cardiovascular screening campaign in the Greater Casablanca region, involving more than 10,000 adults aged over 40 years. This 10-year follow-up study aims to evaluate long-term cardiovascular outcomes and to develop a Morocco-specific cardiovascular risk score. Follow-up data will be collected through phone calls, WhatsApp, or SMS with participants or their families to document cardiovascular deaths, myocardial infarctions, and strokes. Statistical analyses, including survival analysis and multivariate logistic regression, will be used to identify significant risk factors and to construct a predictive risk model tailored to the Moroccan population. The study received a favorable opinion from the Rabat Ethics Committee. Written informed consent will be obtained from all participants or their families prior to data collection. The findings are expected to enhance understanding of cardiovascular risk evolution in Morocco and to provide a validated, population-specific risk score to support prevention and patient management strategies.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Day
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Participants screened for cardiovascular risk (TAC cohort) | – | –Participants aged 40 years and older who were screened for cardiovascular risk between 2010 and 2012 by the "All with heart" Association in the Greater Casablanca region. This cohort is being followed 10 years after the initial screening to assess cardiovascular outcomes (death, myocardial infarction, stroke) and to develop a Morocco-specific cardiovascular risk score. No intervention is applied; the study is purely observational. |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population includes adults aged 40 years and older who were screened for cardiovascular risk between 2010 and 2012 by the "All with heart" Association in the Greater Casablanca region, Morocco. Approximately 10,000 individuals participated in the original screening campaign, which collected data on anthropometric, biological, and lifestyle risk factors. For the 10-year follow-up, all eligible Moroccan participants from the initial screening will be contacted by phone, WhatsApp, or SMS to collect updated information on cardiovascular events, hospitalizations, and mortality. This population represents a community-based cohort reflecting the general adult population at risk of cardiovascular disease in Morocco.
Key inclusion criteria (4 listed)
- Adults aged 40 years or older at the time of the initial screening (2010-2012).
- Individuals who participated in the cardiovascular risk screening campaign conducted by the "All with heart" Association between 2010 and 2012 in the Greater Casablanca region.
- Moroccan nationality.
- Participants or family members who provide written informed consent for participation in the 10-year follow-up study.
Key exclusion criteria (4 listed)
- Individuals who refuse to participate in the follow-up study.
- Participants who have moved and cannot be reached by phone, WhatsApp, or SMS.
- Participants who died from non-cardiovascular causes.
- Non-Moroccan participants.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Incidence of Major Cardiovascular Events (MACE)
Time frame: 10 years after initial screening (2010-2012)
Occurrence of major cardiovascular events (myocardial infarction, stroke, or cardiovascular death) among participants screened for cardiovascular risk between 2010 and 2012 by the "All with heart" Association. Events will be identified during the 10-year follow-up period through participant or family contact (phone, WhatsApp, or SMS) and verified through available medical records when possible.
Development and Validation of a Morocco-Specific Cardiovascular Risk Score
Time frame: Baseline (2010-2012) and 10-year follow-up (2022)
Development and internal validation of the Morocco-Specific Cardiovascular Risk Score, a composite risk prediction score estimating the 10-year probability of major cardiovascular events including myocardial infarction, stroke, or cardiovascular death. The score will be derived from baseline cardiovascular risk factors collected during the initial screening and weighted using multivariable regression models based on outcomes observed during the 10-year follow-up. The score will be expressed on a scale ranging from 0 to 100, where higher scores indicate a higher cardiovascular risk and therefore a worse outcome. Model performance will be assessed using discrimination and calibration measures, including the area under the receiver operating characteristic curve and calibration analyses.
1 secondary outcome
Incidence of Minor Cardiovascular Events
Time frame: 10 years after initial screening (2010-2012)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Dec 2025.
- Individual participant dataSharing planned: No. The sharing of individual participant data (IPD) is not authorized by the Ethics Committee of Rabat. According to the committee's decision, data collected in this study are strictly confidential and may only be used by the research team for the purposes defined in the approved protocol. All collected data will remain stored securely and will not be shared with other researchers or institutions to ensure compliance with national data protection regulations and the ethical approval obtained for this study.
Related trials for Cardiovascular Diseases (CVD)
Active, not recruitingPhase 3
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Ischemic Optic Neuropathy
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Mohamed ALAMI contact
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiovascular Diseases (CVD), run by Moroccan Society of Cardiology at 2 sites in Morocco.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Morocco. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Najat MOUINE, Professor of Cardiology (+212661202733, mouine2@yahoo.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Major Cardiovascular Events (MACE) (time frame: 10 years after initial screening (2010-2012)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2025.